SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Adler LA, Chua HC. Management of ADHD in adults. J. Clin. Psychiatry 2002; 63 (Suppl 12): 2933.
  • 2
    Barkley RA. Attention Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment, 2nd edn. Guilford Press, New York, 1998.
  • 3
    Biederman J, Petty C, Fried R et al. Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 2006; 163: 17301738.
  • 4
    Weiss G, Hechtman LT. Hyperactive Children Grown Up: ADHD in Children, Adolescents, and Adults. Guilford Press, New York, 1993.
  • 5
    Faraone SV, Biederman J, Spencer T et al. Attention-deficit/hyperactivity disorder in adults: An overview. Biol. Psychiatry 2000; 48: 920.
  • 6
    Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. Psychiatr. Clin. North. Am. 2004; 7: 187201.
  • 7
    Tanaka Y. Attention-deficit hyperactivity disorder in adulthood: the current state and problems. J. Psychiatr. Treat. 2004; 19: 415424.
  • 8
    Montano B. Diagnosis and treatment of ADHD in adults in primary care. J. Clin. Psychiatry 2004; 65: 1821.
  • 9
    Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002; 27: 699711.
  • 10
    Heil SH, Holmes HW, Bickel WK et al. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 2002; 67: 149156.
  • 11
    Ring BJ, Gillespie JS, Eckstein JA, Wrighton SA. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab. Dispos. 2002; 30: 319323.
  • 12
    Sauer JM, Ponsler GD, Mattiuz EL et al. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. Drug Metab. Dispos. 2003; 31: 98107.
  • 13
    Shimizu T, Ochiai H, Asell F et al. Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metab. Pharmacokinet. 2003; 18: 4870.
  • 14
    Takahashi M, Takita Y, Yamazaki K et al. A randomized, double-blind, placebo-controlled study of atomoxetine in Japanese children and adolescents with attention-deficit/hyperactivity disorder. J. Child Adolesc. Psychopharmacol. 2009; 19: 341350.
  • 15
    Michelson D, Adler L, Spencer T et al. Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol. Psychiatry 2003; 53: 112120.
  • 16
    Spencer T, Biederman J, Wilens T et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am. J. Psychiatry 1998; 155: 693695.
  • 17
    Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). Multi-Health Systems Inc, North Tonawanda, 1999.
  • 18
    Takahashi M, Takita Y, Ichikawa H et al. Reliability and validity of the Japanese version of CAARS-Screening version (CAARS-SV), Adult ADHD symptom rating scale. Clin. Psychiatry 2011; 53: 2334.
  • 19
    Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Department of Health, Education, and Welfare, Bethesda, MD, 1976.
  • 20
    National Institute of Mental Health. Clinical global impression scale. Psychopharmacol. Bull. 1985; 21: 839943.
  • 21
    Adler L, Dietrich A, Reimherr FW et al. Safety and tolerability of once versus twice daily atomoxetine in adults with ADHD. Ann. Clin. Psychiatry 2006; 18: 107113.
  • 22
    Adler LA, Spencer T, Brown TE et al. Once-daily atomoxetine for adult attention-deficit/hyperactivity disorder: a 6-month, double-blind trial. J. Clin. Psychopharmacol. 2009; 29: 4450.